Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VRDN 
Viridian Therapeutics Inc (VRDN)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/02/2025: VRDN (4-star) is a STRONG-BUY. BUY since 126 days. Simulated Profits (115.05%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $39.41
1 Year Target Price $39.41
| 9 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.9% | Avg. Invested days 48 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.90B USD | Price to earnings Ratio - | 1Y Target Price 39.41 |
Price to earnings Ratio - | 1Y Target Price 39.41 | ||
Volume (30-day avg) 16 | Beta 0.94 | 52 Weeks Range 9.90 - 32.54 | Updated Date 12/3/2025 |
52 Weeks Range 9.90 - 32.54 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.9532 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) -56.7% |
Management Effectiveness
Return on Assets (TTM) -30.4% | Return on Equity (TTM) -49.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2769930575 | Price to Sales(TTM) 41.03 |
Enterprise Value 2769930575 | Price to Sales(TTM) 41.03 | ||
Enterprise Value to Revenue 39.13 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 95367908 | Shares Floating 90025674 |
Shares Outstanding 95367908 | Shares Floating 90025674 | ||
Percent Insiders 0.14 | Percent Institutions 100.56 |
Upturn AI SWOT
Viridian Therapeutics Inc
Company Overview
History and Background
Viridian Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for patients with serious and rare diseases. Founded in 2017, Viridian is headquartered in Waltham, Massachusetts. The company initially focused on thyroid eye disease (TED) and is expanding into other autoimmune diseases.
Core Business Areas
- Thyroid Eye Disease (TED): Development and commercialization of therapies targeting IGF-1R for TED, aiming to improve outcomes for patients with this debilitating autoimmune condition.
Leadership and Structure
The leadership team includes Scott Myers (CEO), Barrett Katz, MD (Chief Medical Officer), and other experienced executives. The organizational structure is typical of a clinical-stage biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- VRDN-001: VRDN-001, an IV-administered IGF-1R antibody, is Viridian's lead candidate for TED. Currently in Phase 3 development. Competitors include Tepezza (Horizon Therapeutics) and potential biosimilars. VRDN-001 aims to provide a more convenient and potent treatment option than Tepezza.
- VRDN-002: VRDN-002, a subcutaneous IGF-1R antibody, is being developed for TED maintenance therapy and potentially other indications. Competitors would be oral medicines and lower cost biosimilars if they exist. This aims to reduce treatment burden for patients.
- VRDN-003: VRDN-003 is a subcutaneous injection for patients with Thyroid Eye Disease. Still in early development so minimal information on competition.
Market Dynamics
Industry Overview
The biotechnology industry, specifically in the autoimmune disease sector, is characterized by high growth potential, intense competition, and significant regulatory hurdles. The market for TED therapies is expanding due to increased awareness and improved diagnosis.
Positioning
Viridian is positioning itself as a leader in TED therapeutics by developing more convenient and potentially more effective treatments than existing options. Their competitive advantage lies in the potential for superior efficacy and patient convenience with their subcutaneous formulations.
Total Addressable Market (TAM)
The total addressable market for TED therapies is estimated to be in the billions of dollars. Viridian is positioned to capture a significant share of this market with its pipeline of IGF-1R antibodies.
Upturn SWOT Analysis
Strengths
- Strong pipeline of IGF-1R antibodies for TED
- Potential for more convenient subcutaneous formulations
- Experienced management team
- Positive early clinical data
Weaknesses
- Reliance on a single therapeutic area (TED)
- Limited commercial infrastructure
- Risk of clinical trial failures
- Dependence on regulatory approvals
Opportunities
- Expansion into other autoimmune diseases
- Partnerships with larger pharmaceutical companies
- Potential for orphan drug designation
- Increasing awareness of TED
Threats
- Competition from established therapies (e.g., Tepezza)
- Development of biosimilars
- Changes in regulatory landscape
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- HZNP
Competitive Landscape
Viridian's advantage lies in potentially improved efficacy and route of administration (subcutaneous vs intravenous) compared to existing therapies. Disadvantages include being a smaller company with less commercial experience than Horizon Therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of its pipeline through preclinical and clinical stages.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its TED therapies. Analyst estimates vary but generally project significant revenue growth in the coming years.
Recent Initiatives: Recent initiatives include advancing VRDN-001 and VRDN-002 through Phase 3 clinical trials and expanding its pipeline into additional autoimmune indications.
Summary
Viridian Therapeutics is a promising clinical-stage biotechnology company focused on developing novel therapies for thyroid eye disease. The company's strength lies in its pipeline of IGF-1R antibodies and potential for more convenient subcutaneous formulations. However, it faces competition from established therapies and the risks associated with clinical development and regulatory approval. Successful execution of clinical trials and commercialization will be critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viridian Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2014-06-18 | CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | |
Full time employees 143 | |||
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.